Patrys gets new EU patent for PAT-SM6
Patrys (ASX:PAB) has been granted a third European patent for anticancer candidate PAT-SM6, securing protection through to 2027.
The company has secured a patent from the European Patent Office covering a “novel glycosylated target in neoplastic cells”.
The patent protects the use of PAT-SM6 in various blood and solid cancers including myeloma, melanoma, lung, breast, pancreatic, kidney, colon, cervical and brain.
With the new patent, Patrys now has nine patents covering the candidate in Europe, Australia, the US and Japan, and additional applications pending in Canada, the US and Japan.
Patrys is trialling PAT-SM6 in multiple myeloma and has been awarded orphan drug status in the indication by the US FDA.
The company recently released the results of a phase I/II trial showing that PAT-SM6 was found to safe and well tolerated at each dose level tested.
But Patrys was recently forced to postpone another planned trial until the second quarter of 2015 due to unexpected complications manufacturing the drug for the study.
Patrys (ASX:PAB) shares grew from $0.011 to $0.015 on Wednesday after the company revealed it had been granted the new European patent. The shares have since declined to $0.013 as of around 1.30 pm on Friday.
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
